SIREN : 789422052
LOROMED is a French company founded 13 years ago, specialized in the sector Autres activités de soutien aux entreprises n.c.a.. Based in SAINT-JEAN (31240), this company of category PME shows in 2024 a revenue of 2 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 116 € | 2 489 € | N/C | N/C | 2 000 € | 4 600 € | N/C | 18 600 € | 4 877 € |
| Net income | -16 813 € | -2 999 € | -9 573 € | -7 347 € | -27 627 € | 99 897 € | 174 403 € | 7 332 € | 862 € |
| EBITDA | -5 128 € | -5 180 € | -7 350 € | -7 348 € | -4 946 € | -4 572 € | -20 274 € | 10 243 € | -4 947 € |
| Net margin | -794.6% | -120.5% | N/C | N/C | -1381.3% | 2171.7% | N/C | 39.4% | 17.7% |
In 2024, LOROMED achieves revenue of 2 k€. Revenue is declining over the period 2016-2024 (CAGR: -9.9%). Significant drop of -15% vs 2023. After deducting consumption (0 €), gross margin stands at 2 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -5 k€, representing -242.3% of revenue. Warning negative scissor effect: despite revenue change (-15%), EBITDA varies by +1%, reducing margin by 34.2 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -17 k€ (-794.6% of revenue), which will impact equity.
2 116 €
2 116 €
-5 128 €
-5 083 €
-16 813 €
-242.3%
The debt ratio (= Financial debt / Equity x 100) stands at 4%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 92%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
3.726%
91.608%
-240.217%
-0.401
In 2024, the debt ratio of LOROMED (3.73) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of LOROMED (91.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of LOROMED (-0.40) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 913.44. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
913.436
-228.744
In 2024, the liquidity ratio of LOROMED (913.44) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of LOROMED (-228.7x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 198 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 103 days. The gap of 95 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 4122 days of revenue, i.e. 24 k€ to permanently finance. Over 2016-2024, WCR increased by +214%, requiring additional financing.
24 230 €
198 j
103 j
0 j
4122 j
Based on 131 transactions of similar company sales (all years), the value of LOROMED is estimated at 754 € (range 376€ - 1 426€). The price/revenue ratio is 0.36x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 131 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare LOROMED with other companies in the same sector:
Voir toutes les statistiques du secteur Autres activités de soutien aux entreprises n.c.a.
The revenue of LOROMED in 2024 is 2 k€.
LOROMED recorded a net loss in 2024.
The headquarters of LOROMED is located in SAINT-JEAN (31240), in the department Haute-Garonne.
The tax return of LOROMED is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
LOROMED operates in the sector Autres activités de soutien aux entreprises n.c.a. (NAF code 82.99Z). See the 'Sector positioning' section above to compare the company with its competitors.